Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from EQL Pharma AB ( (SE:EQL) ) is now available.
EQL Pharma AB, a Lund-based generics specialist listed on Nasdaq Stockholm, focuses on niche prescription generics for the Nordic and wider European markets and partners extensively with contract manufacturers to support its expanding product pipeline. Its portfolio of 47 launched niche generics underpins a strategy centered on hospital and other prescription drugs with limited competitive pressure.
The company has initiated the recruitment of a new Chief Supply Chain Officer with a strong CMO and CDMO background, as current CSCO Magnus Erreth will remain until mid-June 2026 to ensure a stable transition. The leadership change in supply chain, occurring amid a challenging supply environment, signals EQL Pharma’s intent to reinforce its sourcing and manufacturing capabilities, with further details on the appointment to be provided in due course.
More about EQL Pharma AB
EQL Pharma AB is a Lund-based pharmaceutical company specializing in the development and sale of generic prescription drugs, with a focus on niche generics that face limited competition beyond the original products. The company has 47 such niche generics launched in Nordic markets, a substantial pipeline of additional products for Europe, and collaborates with leading contract manufacturers and major pharma firms across the EU and Asia.
YTD Price Performance: -12.28%
Average Trading Volume: 28,262
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.5B
See more data about EQL stock on TipRanks’ Stock Analysis page.